Ben Fidler, deputy editor of biotechnology at Xconomy, is departing the website.
He has been at Xconomy since April 2013.
“Thanks to Xconomy for the opportunity, my colleagues for being true family, and to all you readers for the support and insightful feedback over the years!” he wrote on Twitter.
Fidler joined Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming.
He was The Deal’s senior health care writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Fidler wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act.
Before switching to the health care beat, Fidler was The Deal’s senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others.
